IP Library Patent Application 18552975
Patent Application
App. No. 18/552,975

ALKALI METAL SALT COMBINATIONS OF INCOMPATIBLE ACTIVE PHARMACEUTICAL INGREDIENTS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/552,975
Abstract

A composition comprises an alkali metal salt of a first pharmaceutical ingredient; and a second pharmaceutical ingredient, wherein the second pharmaceutical ingredient is chemically incompatible with the first pharmaceutical ingredient, and the composition is an aqueous solution. The first active pharmaceutical ingredient can comprise ibuprofen or naproxen. The second pharmaceutical ingredient can comprise acetaminophen.

Claims (15)

1 . A composition comprising:

an alkali metal salt of a first pharmaceutical ingredient; and

a second pharmaceutical ingredient,

wherein the second pharmaceutical ingredient is chemically incompatible with the first pharmaceutical ingredient, and the composition is an aqueous solution.

2 . The composition of claim 1 , wherein the alkali metal is sodium, potassium, or a combination of both.

3 . The composition of claim 1 , wherein 40%-100% of the first active pharmaceutical ingredient is the alkali metal salt.

4 . The composition of claim 1 , wherein at least 4%-85% of the first active pharmaceutical ingredient is the alkali metal salt.

5 . The composition of claim 2 , wherein the balance of the first active pharmaceutical ingredient is non-ionized.

6 . The composition of claim 1 , wherein the first active pharmaceutical ingredient comprises ibuprofen, naproxen, ketoprofen, dexibuprofen, fenoprofen, dexketoprofen, flurbiprofen, oxaprozin, loxoprofen, diflunisal, etodolac, indomethacin, ketorolac, oxaprozin, piroxicam, salsalate, salicylic acid, indomethacin, tolmetin, sulindac, etodolac, ketordolac, diclofenac, aceclofenac, bromfenac, pharmaceutically acceptable salts thereof, or any combination thereof.

7 . The composition of claim 1 , wherein the first active pharmaceutical ingredient comprises ibuprofen or naproxen.

8 . The composition of claim 6 , wherein the second active pharmaceutical ingredient comprises acetaminophen, phenylephrine, chlorpheniramine and dextromethorphan, cetirizine, pseudoephedrine, brompheniramine, guaifenesin, doxylamine, or any combination thereof.

9 . The composition of claim 7 , wherein the second active pharmaceutical ingredient comprises acetaminophen.

10 . The composition of claim 1 , further comprising polyethylene glycol (PEG), methoxy-PEG (mPEG), derivatives thereof, and/or any combination thereof.

11 . The composition of claim 10 , wherein PEG is PEG-200 to 1500.

12 . A softgel capsule comprising a fill comprising the composition of claim 1 .

Assignments (2)
CHANGE OF NAME Recorded Jan 18, 2024
From: GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS (US) LLC
To: HALEON US HOLDINGS LLC
Reel/Frame 066344/0609 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 28, 2023
From: ANDERSON, GARY BRUCE; BAILEY, HOPE PATRICIA; BOGGIA, JONATHON MICHAEL; KINTER, KEVIN SCOTT; MOORE, RACHEL ELIZABETH; PATEL, JIGNA DHANU; PATEL, SHIVANGI AKASH
To: GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS (US) LLC
Reel/Frame 065062/0028 →